Skip to Main Content
Contribute Try STAT+ Today

Making a drug is a bit like baking — in the goopiest, messiest sense possible. Just ask Janet Woodcock, director of the Food and Drug Administration’s Center for Drug Evaluation and Research.

“We take the [inactive] and active [ingredients] and put them into a giant pot. It looks like a gigantic cake mixer. And then we … take that mush and we squeeze it out into a string and put it into tablets,” said Woodcock. “It’s a mess, it gets all over the place.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Blending of solids and liquids has been practiced to suit application and use needs. That is fundamental chemical engineering. I have no clue what Jonathan is talking about. It has been perfected and advanced in every industry except for pharmaceuticals. Thus to me and many others it is no innovation. May be to pharmaceutical industry and regulators it is new as they seem to be living in Stone Age.

  • While I applaud the enthusiasm of the author, the time frame is a bit off. “One challenge is that, to make drugs continuously, companies also need to ensure drug quality continuously.” This line reflects PAT (Process Analytic Technology) which is something the FDA was pushing industry toward around 2005 – because it would make ‘Continuous process’ possible. This has been in the pipeline for a long time – finally coming to fruition. (And to show my NJ bias, with a great deal of work done at Rutgers School of Engineering in this area, as well as NJIT.)
    Note the date of this article if you chose to read it:

Comments are closed.